Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
Data from the Centers for Disease Control and Prevention showed an increase in three respiratory viruses—COVID-19, flu and RSV—and the gastrointestinal disease norovirus. Emergency department ...
Emergency department visits are "high" and "very high" for flu and RSV, respectively, and "elevated" for COVID-19 across the U.S., according to the CDC. As of the week ending Jan. 4, 18.6% of ...
After seeing its Covid-19 drug fail in a Phase 3 trial last year, Shionogi on Thursday won a $375 million award from HHS to develop … ...
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...
Respiratory syncytial virus (RSV) causes cold-like symptoms in most people but can cause more serious problems in some, especially babies and older adults. Almost all children get RSV at least once by ...
Winter also marks the height of the respiratory virus season, a period of sniffles, sneezes, congestion, fever and other maladies brought about primarily by four pathogens: the respiratory syncytial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback